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ALTERNATIVES TO CYVADIC-COMBINATION OF SOFT TISSUE SARCO-MA J. H. Hartlapp, H. J. llliger, H. Wolter For more than 10 years the combination of cyclophosphamide, vincristine, adriamycin and dacarbazine is the favoured chemotherapy for soft tissue sarcomas. The remission rate reaches up to 55 % with a cumulative rate of 35 %. There are many trials to improve these therapy results.ln a phase IT-study we examined a combination of cis-platinum and ifosfamide on 68 pts. with a locally advanced or metastasized soft tissue sarcoma. The most frequent histologic entities were fibrosarcomas (n=23) and leiomyosarcomas (n=17). The treatment regimen was 1,5 g/m 2 ifosfamide and 20 mg/m ~ cis-platinum per day over 5 days. We achieved a CR in 7/68 pts. and a PR in 23 pts., this means a remission rate of 44 %. Side-effects were severe nausea and vomiting, on the other hand leucopenia and anemia as well as a geoeral malaise, especially with a successive chemotherapy of more than 4 cycles. In consequence of these side-effects, which we essentially attributed to cis-platinum, we substituted cis-platinum by 50 mg/m 2 adriamycin, distributed on 3 days, in 21 further pts. 3 of these 21 pts. achieved a CR and 9 PR. 4 further pts. with progressive disease came to a stable state for 4,6,9 and 11 months. The gastrointestinal side-effects were significantly lower compared with the combination of ifosfamide and cis-platinum, vomiting being completely suppressed. There was only a moderate bone marrow toxicity: only in 3 pts. leucocytes fell below 2000 and only in S pts. platelets were below 70000. Despite the small number of pts. the combination of ifosfamide and adriamycin can be proposed as an alternative therapy for soft tissue sarcomas. On account of the lower toxicity and similar therapy results this combination should be proved on further pts. Remission rates and duration of remissions of 23 patients (15 male, 8 female) with disseminated soft tissue sarcomas will be presented. First line chemotherapy was: Adriamycin 60 mg/m 2 day I end DTIC 600 mg/m 2 days I and 2. SeeQnd line chemotherapy in ncn-responding or relapsing patients was: Cisplatin 80 mg/m 2 day I and Ifosfamid 1.5 g/m ~ days I-5. Adaequate hydration and uroprophylaxis with Mesna was given. The median age was 44 years (I 6 to 70 years). ~ne material cc~prises the following tumorentities: Malignant fibrous histiocytoma 5, rhabdcxnyosarcoma 4, malignant schwanncmm 4, leiomyosarcc~a 3, hemangioparicytoma 2, angiosarcoma 2, mesodermal mixed tumor I, fibrosarcoma I, anaplastic carcoma I. 12/23(=52%) patients responded to Adriamycin/DTIC therapy with a ccmplete or partial remission. Remission duration ranged frc~ I to 12 months with a median of 5,5 montb~. 13 patients (7non-responding to Adriar~[/c~/DTIC, 6 relapsing)were subsequently treated with the second line re--gimen Ifosfamid/Cisplatin. 5/I 3 (=38%) achieved a partial remission with a duration from 3 to 12 months (median 7,4 months). 4/5 of the second line responders had responded to the first line regimen whereas only I of the first line non-responders achieved remission with the second line chemotherapy.
Side effect were apart from nausea, vc~it-ting end alopecia severe leucopenia in one patient with Adrism~cin/DTIC, severe leucope~ia and thrombopenia in 4 patients with Ifosfamid/Cisplatin. Data of this trial suggest: (I) ADM/DTIC in a 2-day schedule regimen seems to be as effective as CYVADIC or ADM / DTIC in a 5-day regimen. (2) Ifosfamid/Cisplatin seems to be an effective second line therapy in soft tissue sarcc~a. We administered a total of 109 cycles with a medinm of 3.3 cycles per pat.. In i0 pts the Ifo treatment was given primarily with a remission rate of 8/19 (42 %). 14 pts received this therapy as second line following CYVADIC. Surprisingly we met a similar response rate of 6/14 (43 %). Looking for the details we found that a second remission was confined in all but one cases on those pts who had already responded to CYVADIC.
